| Original language | English (US) |
|---|---|
| Pages (from-to) | e7 |
| Journal | The lancet oncology |
| Volume | 23 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
ASJC Scopus subject areas
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The lancet oncology, Vol. 23, No. 1, 01.2022, p. e7.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Assessment of tumour-agnostic therapies in basket trials
AU - Popat, Sanjay
AU - Ramagopalan, Sreeram V.
AU - Ray, Joshua
AU - Roze, Stéphane
AU - Subbiah, Vivek
N1 - Funding Information: SP reports being a consultant for Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Guardant Health, Incyte, Janssen, Eli Lilly, Merck, Novartis, Roche, Takeda, Pfizer, Seattle Genetics, Turning Point Therapeutics, and Xcovery outside the submitted work. VS reports grants from Eli Lilly/Loxo Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals, and Helsinn Pharmaceuticals outside the submitted work; grants and advisory board or consultant positions with Eli Lilly/Loxo Oncology outside the submitted work; research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune outside the submitted work; an advisory board or a consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay therapeutics, Roche, and Medimmune outside the submitted work; travel funds from Pharmamar, Incyte, ASCO, and ESMO outside the submitted work; and educational fund support from Medscape outside the submitted work. SVR and JR are employees of F. Hoffmann-La Roche. SR declares no competing interests.
PY - 2022/1
Y1 - 2022/1
UR - http://www.scopus.com/inward/record.url?scp=85121912710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121912710&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(21)00714-2
DO - 10.1016/S1470-2045(21)00714-2
M3 - Letter
C2 - 34973234
AN - SCOPUS:85121912710
SN - 1470-2045
VL - 23
SP - e7
JO - The lancet oncology
JF - The lancet oncology
IS - 1
ER -